


Development of an evidence-based specialty pharmacy program for hemophilia

Kristen Ditch¹, PharmD, BCCCP; Jennifer L. Donovan¹, PharmD; Brooke Ruhland¹, PharmD, CSP; Brian S. Smith¹, PharmD; Melissa Racine¹, MS, RN; Lauren Mills¹, Kate Campagnola¹, PharmD; Ameet Wattamwar², PharmD; Kate Smullen¹, PharmD, CSP; Stacy Walton¹, RN, BSN 1 – Shields Health Solutions, Stoughton, MA; 2 – NYU Langone Hospitals, New York, NY





Background

- Hemophilia patients have complex treatment regimens requiring enhanced specialized care and expertise. It is essential for specialty pharmacies to develop and support a comprehensive care model to manage hemophilia patients
- The National Hemophilia Foundation's Medical and Scientific Advisory Council (MASAC) recommendations regarding standards of service for pharmacy providers of clotting factor concentrates states qualified specialty pharmacies must be knowledgeable, comprehensive, timely and accurate, accessible, safe and thorough to ensure quality care is delivered¹
- In January 2020, UMass Memorial Medical Center, Worcester, MA, an academic medical center specialty pharmacy, launched a pharmacistnurse hemophilia program to deliver customized care

Objective

• To describe the process of designing and implementing an evidencebased hemophilia program that uses a pharmacist-nurse clinical model to deliver comprehensive patient care

Methods

- A literature search between 1/1/2010 to present was conducted to identify clinically meaningful hemophilia outcomes and their associated definitions
- MASAC treatment guidelines were searched for recommendations pertaining to the outpatient management of hemophilia patients
- Data elements required by commercial payors in the hemophilia market, and accreditation standards pertaining to specialty pharmacy, were compiled
- These data elements were built into an internal patient management platform (PMP) utilized by a hemophilia nurse and specialty pharmacists to track patient outcomes and to perform patient outreach while implementing customized care plans
- The specialty pharmacy established home infusion nursing services by identifying home infusions agencies used by the hemophilia patients and in collaboration with the hematologists. Calls were placed to two home infusion companies preferred by patients in the region and contracts with the specialty pharmacy were established

Results Hemophilia Clinical Nurse Assessments Evaluate for Clinical Follow referral to Clinical Initia o Assessmen home infusion Assessment every 6 nursing months Initiate services Onboarding Assessment Patient Care nitial Activit Complete Bleed Assessment in the Patient Care PMP to capture required questions, nave a recent ssess the clinical status of the patient Refill Activity and modify therapy if needed Perform patient outreach Work with the specialty Ensure proper infusion answer required questions pharmacy to perform assay supplies are delivered to the Refill Wo in the PMP, assess the management and achieve Does Patient patient and assess need for need a refill? clinical status of the the lowest percent variance home infusion nursing patient and modify between dose ordered and services therapy if needed dose dispensed Reconcile infusion supplies —> Pend refill follow-up for a future date **Contract Nursing Services** Two home infusion nursing The hemophilia nurse makes a referral to one of the agencies and provides the following information: Patient demographics, medication or supply order(s), and a agencies were identified, and contracts established description of intravenous access **Commercial Payors** A total of 25 unique requirements that fall into the following categories were 11 Commercial payors identified incorporated into the PMP: • Clinical interventions | • Assay management

• Bleed management

management)

Clinical outcomes (e.g., target joints, inhibitor

Medication adherence

Baseline parameters

Results (continued)

Accreditation Standards		
Repartments Patient Requirements	The following patient managing incorporated in to the PMP:	gement focus areas were
	 Clinical assessments Goals of therapy Education & counseling Clinical interventions Prescription information Benefits investigation 	 Patient demographics Medication list Drug utilization review Welcome packet Functional limitations Copay & copay assistance
Clinically Meaningful Hemophilia Outcomes		
Clinical outcomes dentified	The following clinical outcor PMP:	nes were incorporated into the
	 Hemophilia related comorbid conditions Pain assessment Timeliness to treat² Vaccination status 	 Annualized bleeding rate³ Life-threatening bleeds Evaluation of supply on-hand⁴ Medication regimen⁵ Monitoring dental visits

Conclusions

- A systematic approach to gathering requirements from payors, accreditation organizations, and clinical best practices served as a foundation to build a hemophilia program
- On-going evaluation of patient care outcomes will serve to validate the quality care provided by the hemophilia nurse and specialty pharmacists

References

- Medical and Scientific Advisory Committee. MASAC recommendation regarding Standards of Service for Pharmacy Provider of Clotting Factor Concentrates for Home Use to Patients with Bleeding Disorders. MASAC Document # 188. National Hemophilia Foundation 2008.
- Srivastava A, et al. WFH Guidelines for the management of hemophilia. Haemophilia 2013;19, e1-e47
 Chai-Adisaksopha C., et al. A systematic review of definitions and reporting of bleeding outcome measures in haemophilia. Haemophilia 2015; 21: 731-
- Medical and Scientific Advisory Committee. MASAC recommendation regarding home factor supply for emergency preparedness for patients with emophilia and other bleeding disorders. MASAC Document #227. National Hemophilia Foundation 2014.
- Medical and Scientific Advisory Committee. MASAC recommendation regarding recommendation on the use and management of emicizumab-KXWH (Hemlibra®) for hemophilia A with and without inhibitors. MASAC Document # 255. National Hemophilia Foundation 2018.

Disclosures

The authors of this presentation have the following to disclosure concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation.

KD: Employee of Shields Health Solutions